Factors of hyperlipidemia medication adherence in a nationwide health plan

American Journal of Managed Care

Volumn 18, Issue 4, 2012, Pages 193-199

  Wiegand, Phillip ^a   McCombs, Jeffery S ^b   Wang, Jennifer J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Wellpoint Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; FEMALE; GENDER; HEALTH CARE PLANNING; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACY; PHYSICIAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; COST SHARING; DATABASES, FACTUAL; FEMALE; HEALTH BEHAVIOR; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; UNITED STATES;

EID: 84860784558     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-e209.
2. Peeters A, Mamun AA, Willekens F, Bonneux L. A cardiovascular life history: a life course analysis of the original Framingham Heart Study cohort. Eur Heart J. 2002;23(6):458-466. (Pubitemid 35204185)
3. Schweikert B, Hunger M, Meisinger C, et al. Quality of life several years after myocardial infarction: comparing the MONICA/KORA registry to the general population. Eur Heart J. 2009;30(4):436-443.
4. Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics. 2003;21(3):191-200. (Pubitemid 36286663)
5. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006;144(5): 326-336. (Pubitemid 46768187)
6. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterolin Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-1622.
8. Shepherd J, Cobbe SM, Ford I, et al West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333(20): 1301-1307.
9. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-696. (Pubitemid 39140624)
10. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to preventvascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
11. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461. (Pubitemid 34787476)
12. Thiebaud P, Patel BV, Nichol MB, Berenbeim DM. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care. 2005;11(11):670-674. (Pubitemid 41608208)
13. Blake GJ, Ridker PM, Kuntz KM. Potential cost-effectiveness of Creactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Am J Med. 2003;114(6):485-494. (Pubitemid 36515111)
14. Perreault S, Blais L, Lamarre D, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol. 2005;59(5):564-573. (Pubitemid 40632247)
15. Sung JC, Nichol MB, Venturini F, et al. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care. 1998;4 (10):1421-1430. (Pubitemid 28506805)
16. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12. (Pubitemid 46161090)
17. Grant RW, O'Leary KM, Weilburg JB, Singer DE, Meigs JB. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med. 2004;164(21):2343-2348. (Pubitemid 39532245)
18. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165(10):1147-1152. (Pubitemid 40720739)